Long-Term Seizure Outcomes Between Combined Vagus Nerve Stimulation and Corpus Callosotomy and Corpus Callosotomy Alone in Patients with Refractory Multifocal or Generalized Epilepsy: A Comparative Study
Aug 2026· Asian Journal of Neurosurgery· 0 citations· 25 references
TL;DR
The combined treatment of CC and VNS has shown considerable efficacy in the management of multifocal and generalized epilepsy, and further research is needed to establish the potential therapeutic benefit of integrating next-generation neuromodulatory modalities, including VNS, DBS and responsive neurostimulation.
Abstract
Abstract Introduction Epilepsy surgery is considered an established therapeutic modality for achieving seizure control in patients with drug-resistant epilepsy. Surgical interventions are broadly categorized as either curative or palliative, which depend on the identification or absence of a well-defined epileptogenic focus amenable to surgical treatment. Palliative surgical interventions are indicated for patients with medically refractory multifocal or generalized epilepsy who are not suitable candidates for resective surgery. These therapeutic modalities include corpus callosotomy (CC), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and other neuromodulatory strategies. Objective and Material Several studies have reported that the combined application of VNS and CC is associated with favorable seizure outcomes in patients with drug-resistant epilepsy. In this study, the long-term efficacy of the combined application of these two surgical interventions and CC alone in patients with multifocal or generalized epilepsy was assessed over a follow-up period exceeding 10 years. Moreover, 11 patients who underwent the combined treatment of CC and VNS, as well as 7 patients who underwent CC alone, were included; all of whom received surgical treatment through our institution's epilepsy surgery program between 2004 and 2015. All 11 patients initially underwent CC, followed by subsequent implantation of VNS. Results The clinical outcomes following the combined therapeutic approach showed a progressive increase in the proportion of patients achieving a ≥80% reduction in seizure frequency compared with CC alone. Moreover, the therapeutic benefits of the combined intervention were maintained throughout long-term follow-up. Conclusion The combined treatment of CC and VNS has shown considerable efficacy in the management of multifocal and generalized epilepsy. In recent years, palliative surgical approaches have progressively evolved toward neuromodulation-based therapies, driven by advances in emerging technologies. However, further research is needed to establish the potential therapeutic benefit of integrating next-generation neuromodulatory modalities, including VNS, DBS and responsive neurostimulation, which is expected to expand the therapeutic landscape for patients with drug-resistant epilepsy.
Thalamic neuromodulation using DBS and RNS was safe and well tolerated in pediatric patients with DRE, including multifocal and generalized seizure onsets, with a trend toward greater benefit in the DBS group.
Dominic Nistal, Benjamin D. Edmonds, Adriel Barrios-Anderson et al.· Journal of Neurosurgery: Ped...· 0 citations
OBJECTIVE
Drug-resistant epilepsy (DRE) remains a significant clinical challenge, affecting approximately 30% of patients. Deep brain stimulation (DBS) of the centromedian thalamic nucleus (CM) has emerged as a viable therapy for generalized and multifocal seizures. Although high-frequency stimulation (HFS) is the clin...
Julia Vescovi Vieira, João Paulo Santiago Oliveira, R. Guimarães et al.· Epilepsia· 0 citations
In carefully selected patients with drug-resistant non-tumor epilepsy involving or adjacent to eloquent cortex, AC with intraoperative functional mapping appears feasible and may help preserve neurological function while enabling tailored resection.
M. Mofatteh, M. Mashayekhi, Sho Giersztein et al.· BMC Surgery· 0 citations
Objective Deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) is an established palliative therapy for drug-resistant focal epilepsy; however, its efficacy for epileptic spasms (ES) and the clinical utility of unilateral stimulation remain unclear. To address these issues, we report a case of drug-...
Takumi Mitsuhashi, Y. Iimura, Hiroharu Suzuki et al.· Epilepsy & Behavior Reports· 0 citations
Neuromodulation for drug-resistant epilepsy is associated with modest improvements in depression and quality of life without meaningful cognitive deterioration over follow-up durations of 6 months to 14 years.
Margil Ranpariya, Gurleen Kaur, H. Shallwani et al.· Acta Neurologica Belgica· 0 citations
Epilepsy is a chronic neurological disorder characterised by recurrent, unprovoked seizures that can significantly affect morbidity, mortality, and quality of life (QoL). Around 30% of people with epilepsy develop drug-resistant epilepsy (DRE), meaning seizures persist despite treatment with two or more adequate trials...
Amanda Barrell· EMJ Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.